Evidence map›Paper›PMID 38173073›Full record

ReviewCurrent diabetes reviews2025

Stem Cells Reprogramming in Diabetes Mellitus and Diabetic Complications: Recent Advances.

Hafez R Madkor, Mostafa K Abd El-Aziz, Mostafa S Abd El-Maksoud, Islam M Ibrahim, Fares E M Ali

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hafez R MadkorDepartment of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt.
Mostafa K Abd El-AzizFaculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt.
Mostafa S Abd El-MaksoudFaculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt.
Islam M IbrahimFaculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt.
Fares E M AliDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of diabetes mellitus (DM) is dramatically increasing worldwide, and it is expected to affect 700 million cases by 2045. Diabetes influences health care economics, human quality of life, morbidity, and mortality, which were primarily seen extensively in developing countries. Uncontrolled DM, which results in consistent hyperglycemia, may lead to severe life-threatening complications such as nephropathy, retinopathy, neuropathy, and cardiovascular complications. METHODOLOGY: In addition to traditional therapies with insulin and oral anti-diabetics, researchers have developed new approaches for treatment, including stem cell (SC) therapy, which exhibits promising outcomes. Besides its significant role in treating type one DM (T1DM) and type two DM (T2DM), it can also attenuate diabetic complications. Furthermore, the development of insulin- producing cells can be achieved by using the different types of SCs, such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and multiple types of adult stem cells, such as pancreatic, hepatic, and mesenchymal stem cells (MSC). All these types have been extensively studied and proved their ability to develop insulin-producing cells, but every type has limitations.

conclusionThis review aims to enlighten researchers about recent advances in stem cell research and their potential benefits in DM and diabetic complications.

Indexed as

Diabetes ComplicationsStem Cell TransplantationAnimalsCellular ReprogrammingDiabetes MellitusHumansInduced Pluripotent Stem CellsInsulin-Secreting Cellsdiabetes complicationsDiabetes mellitusembryonic stem.mesenchymal stem cellsreprogrammingstem cells therapy

Identifiers

PMID38173073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.